Goal of this study

To treat insomnia in patients with Alzheimer’s disease.


Alzheimer’s disease is a brain disease that gradually destroys memory and thinking skills. This study will investigate the efficacy of a drug named Suvorexant in improving sleep in patients with Alzheimer’s disease. This study will also investigate the safety of Suvorexant. Suvorexant will be given to the patient through the mouth once per night for 4 weeks.

Who can participate in this study?

Patients who have been diagnosed with Alzheimer’s disease and who are between the ages of 50 and 90 may be eligible to participate in this study. This study accepts both men and women and does not accept healthy volunteers.

Important: Additional eligibility criteria apply and the patient’s record will be verified by the study doctor (with the patient’s approval) to confirm eligibility.

Clinicaltrials.gov identifier: NCT02750306

Contact Information

To know if you're eligible to participate in this trial, please fill-up the form below and we will contact you shortly.